Laureate Pharma, Inc. has entered into a contract manufacturing agreement with ImmunoGen, Inc. to manufacture the huC242 antibody used in production of ImmunoGen’s huC242-DM4 Tumor-Activated Prodrug (TAP) compound, now in Phase II clinical testing. Terms of the manufacturing agreement were not disclosed. “ImmunoGen is well known for its proprietary TAP technology, which uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells,” note...